Background: Patients with a history of substance use are more likely than those without substance use to experience chronic noncancer pain (CNCP), to be prescribed opioids, and to experience opioid misuse or overdose. Primary care practitioners (PCPs) in safety-net settings care for low-income patients with CNCP and substance use, usually without specialist consultation. To inform communication related to opioid risk, we explored PCPs’ and patients’ perceptions of the risks of chronic opioid therapy. Methods: We conducted semistructured interviews with 23 PCPs and 46 of their patients, who had a history of CNCP and substance use. We recruited from 6 safety-net health care settings in the San Francisco Bay Area. We transcribed interviews verbatim and analyzed transcripts using grounded theory methodology. Results: (1) PCPs feared harming patients and the community by opioid prescribing. PCPs emphasized fear of opioid overdose. (2) Patients did not highlight concerns about the adverse health consequences of opioids, except for addiction. (3) Both patients and PCPs were concerned about PCPs’ medicolegal risks related to opioid prescribing. (4) Patients reported feeling stigmatized by policies aimed at reducing opioid misuse. Conclusion: We identified differences in how clinicians and patients perceive opioid risk. To improve the informed consent process for opioid therapy, patients and PCPs need to have a shared understanding of the risks of opioids and engage in discussions that promote patient autonomy and safety. As clinics implement opioid prescribing policies, clinicians must develop effective communication strategies in order to educate patients about opioid risks and decrease patients’ experiences of stigma and discrimination.
CherryDK, HingE, WoodwellDA, RechtsteinerEA. National Ambulatory Medical Care Survey: 2006 summary. Natl Health Stat Rep.2008;(3):1–39.
2.
GurejeO, SimonGE, Von KorffM. A cross-national study of the course of persistent pain in primary care. Pain.2001;92:195–200.
3.
VolkowND, McLellanTA, CottoJH, KarithanomM, WeissSR. Characteristics of opioid prescriptions in 2009. JAMA.2011;305:1299–1301.
4.
ChenJH, HumphreysK, ShahNH, LembkeA. Distribution of opioids by different types of medicare prescribers. JAMA Intern Med.2016;176:259–261.
5.
ComptonWM, ThomasYF, StinsonFS, GrantBF. Prevalence, correlates, disability, and comorbidity of DSM-IV drug abuse and dependence in the United States: results from the national epidemiologic survey on alcohol and related conditions. Arch Gen Psychiatry.2007;64:566–576.
6.
BuschSH, MearaE, HuskampHA, BarryCL. Characteristics of adults with substance use disorders expected to be eligible for Medicaid under the ACA. Psychiatr Serv.2013;64:520–526.
7.
CummingsJR, WenH, KoM, DrussBG. Race/ethnicity and geographic access to Medicaid substance use disorder treatment facilities in the United States. JAMA Psychiatry.2014;71:190–196.
8.
PriesterMA, BrowneT, IachiniA, CloneS, DeHartD, SeayKD. Treatment access barriers and disparities among individuals with co-occurring mental health and substance use disorders: an integrative literature review. J Subst Abuse Treat.2016;61:47–59.
9.
Classification of chronic pain. Descriptions of chronic pain syndromes and definitions of pain terms. Prepared by the International Association for the Study of Pain, Subcommittee on Taxonomy. Pain Suppl.1986;3:S1–S226.
10.
MorascoBJ, DuckartJP, DobschaSK. Adherence to clinical guidelines for opioid therapy for chronic pain in patients with substance use disorder. J Gen Intern Med.2011;26:965–971.
11.
FlemingMF, BalousekSL, KlessigCL, MundtMP, BrownDD. Substance use disorders in a primary care sample receiving daily opioid therapy. J Pain.2007;8:573–582.
12.
ManchikantiL, DamronKS, McManusCD, BarnhillRC. Patterns of illicit drug use and opioid abuse in patients with chronic pain at initial evaluation: a prospective, observational study. Pain Physician.2004;7:431–437.
13.
BreckenridgeJ, ClarkJD. Patient characteristics associated with opioid versus nonsteroidal anti-inflammatory drug management of chronic low back pain. J Pain.2003;4:344–350.
14.
EdlundMJ, MartinBC, DevriesA, FanMY, BradenJB, SullivanMD. Trends in use of opioids for chronic noncancer pain among individuals with mental health and substance use disorders: the TROUP study. Clin J Pain.2010;26:1–8.
15.
KobusAM, SmithDH, MorascoBJ, . Correlates of higher-dose opioid medication use for low back pain in primary care. J Pain.2012;13:1131–1138.
16.
WeisnerCM, CampbellCI, RayGT, . Trends in prescribed opioid therapy for non-cancer pain for individuals with prior substance use disorders. Pain.2009;145:287–293.
17.
MorascoBJ, DobschaSK. Prescription medication misuse and substance use disorder in VA primary care patients with chronic pain. Gen Hosp Psychiatry.2008;30:93–99.
18.
IvesTJ, ChelminskiPR, Hammett-StablerCA, . Predictors of opioid misuse in patients with chronic pain: a prospective cohort study. BMC Health Serv Res.2006;6:46.
19.
BeaudoinFL, StraubeS, LopezJ, MelloMJ, BairdJ. Prescription opioid misuse among ED patients discharged with opioids. Am J Emerg Med.2014;32:580–585.
20.
CheatleMD, O'BrienCP, MathaiK, HansenM, GrassoM, YiP. Aberrant behaviors in a primary care-based cohort of patients with chronic pain identified as misusing prescription opioids. J Opioid Manag.2013;9:315–324.
21.
MichnaE, RossEL, HynesWL, . Predicting aberrant drug behavior in patients treated for chronic pain: importance of abuse history. J Pain Symptom Manage.2004;28:250–258.
22.
ReidMC, Engles-HortonLL, WeberMB, KernsRD, RogersEL, O'ConnorPG. Use of opioid medications for chronic noncancer pain syndromes in primary care. J Gen Intern Med.2002;17:173–179.
23.
McCabeSE, CranfordJA, WestBT. Trends in prescription drug abuse and dependence, co-occurrence with other substance use disorders, and treatment utilization: results from two national surveys. Addict Behav.2008;33:1297–1305.
24.
ButlerSF, BudmanSH, FernandezKC, . Development and validation of the Current Opioid Misuse Measure. Pain.2007;130:144–156.
25.
RuddRA, AleshireN, ZibbellJE, GladdenRM. Increases in drug and opioid overdose deaths—United States, 2000–2014. MMWR Morb Mortal Wkly Rep.2016;64:1378–1382.
26.
WebsterLR, CochellaS, DasguptaN, . An analysis of the root causes for opioid-related overdose deaths in the United States. Pain Med.2011;12(Suppl 2):S26–S35.
27.
CoffinPO, GaleaS, AhernJ, LeonAC, VlahovD, TardiffK. Opiates, cocaine and alcohol combinations in accidental drug overdose deaths in New York City, 1990–98. Addiction.2003;98:739–747.
28.
ParkTW, LinLA, HosanagarA, KogowskiA, PaigeK, BohnertAS. Understanding risk factors for opioid overdose in clinical populations to inform treatment and policy. J Addict Med.2016;10:369–381.
29.
Center for Disease Control. Vital signs: overdoses of prescription opioid pain relievers—United States, 1999–2008. MMWR Morb Mortal Wkly Rep.2011;60:1487–1492.
30.
ChenLH, HedegaardH, WarnerM. Drug-poisoning deaths involving opioid analgesics: United States, 1999–2011. NCHS Data Brief.2014;(166):1–8.
31.
JonesCM, MackKA, PaulozziLJ. Pharmaceutical overdose deaths, United States, 2010. JAMA.2013;309:657–659.
32.
CalcaterraS, GlanzJ, BinswangerIA. National trends in pharmaceutical opioid related overdose deaths compared to other substance related overdose deaths: 1999–2009. Drug Alcohol Depend.2013;131:263–270.
33.
AtluriS, SudarshanG, ManchikantiL. Assessment of the trends in medical use and misuse of opioid analgesics from 2004 to 2011. Pain Physician.2014;17:E119–E128.
34.
BohnertAS, ValensteinM, BairMJ, . Association between opioid prescribing patterns and opioid overdose-related deaths. JAMA.2011;305:1315–1321.
35.
DartRC, SurrattHL, CiceroTJ, . Trends in opioid analgesic abuse and mortality in the United States. N Engl J Med.2015;372:241–248.
36.
WarnerM, ChenLH, MakucDM. Increase in fatal poisonings involving opioid analgesics in the United States, 1999–2006. NCHS Data Brief.2009;(22):1–8.
37.
ChouR, FanciulloGJ, FinePG, . Clinical guidelines for the use of chronic opioid therapy in chronic noncancer pain. J Pain.2009;10:113–130.
38.
RutkowL, ChangHY, DaubresseM, WebsterDW, StuartEA, AlexanderGC. Effect of Florida's prescription drug monitoring program and pill mill laws on opioid prescribing and use. JAMA Intern Med.2015;175:1642–1649.
39.
PaoneD, TuazonE, KattanJ, . Decrease in rate of opioid analgesic overdose deaths—Staten Island, New York City, 2011–2013. MMWR Morb Mortal Wkly Rep.2015;64:491–494.
40.
GilsonAM, JoransonDE. U.S. policies relevant to the prescribing of opioid analgesics for the treatment of pain in patients with addictive disease. Clin J Pain.2002;18(4 Suppl):S91–S98.
41.
ManchikantiL, AbdiS, AtluriS, . American Society of Interventional Pain Physicians (ASIPP) guidelines for responsible opioid prescribing in chronic non-cancer pain: part 2—guidance. Pain Physician.2012;15(3 Suppl):S67–S116.
42.
DowellD, HaegerichTM, ChouR. CDC guideline for prescribing opioids for chronic pain—United States, 2016. MMWR Recomm Rep.2016;65:1–49.
43.
AgarinT, TrescotAM, AgarinA, LesanicsD, DecastroC. Reducing opioid analgesic deaths in america: what health providers can do. Pain Physician.2015;18:E307–E322.
44.
JonesCM, LurieP, WoodcockJ. Addressing prescription opioid overdose: data support a comprehensive policy approach. JAMA.2014;312:1733–1734.
45.
The Federation of State Medical Boards of the United States. Model Policy on the Use of Opioid Analgesics in the Treatment of Chronic Pain. Washington, DC: Federation of State Medical Boards of the United States; 2013.
46.
CheatleMD, SavageSR. Informed consent in opioid therapy: a potential obligation and opportunity. J Pain Symptom Manage.2012;44:105–116.
47.
ArnoldRM, HanPK, SeltzerD. Opioid contracts in chronic nonmalignant pain management: objectives and uncertainties. Am J Med.2006;119:292–296.
48.
PattonMQ. Qualitative Research and Evaluation Methods. 3rd ed. Thousand Oaks, CA: Sage Publishers; 2002.
49.
PalinkasLA, HorwitzSM, GreenCA, WisdomJP, DuanN, HoagwoodK. Purposeful sampling for qualitative data collection and analysis in mixed method implementation research. Adm Policy Ment Health.2015;42:533–544.
50.
SametJH, FriedmannP, SaitzR. Benefits of linking primary medical care and substance abuse services: patient, provider, and societal perspectives. Arch Intern Med.2001;161:85–91.
51.
IASP Task Force on Taxonomy III. Pain terms, a current list with definitions and notes on usage. In: MerskeyH, BogdukN, eds. Classification of Chronic Pain. 2nd ed. Seattle, Washington: IASP Press; 1994:209–214.
52.
CharmazK. Constructing Grounded Theory: A Practical Guide Through Qualitative Analysis. Thousand Oaks, CA: Sage Publications; 2014.
53.
CorbinJ, StraussA. Basics of Qualitative Research: Techniques and Procedures for Developing Grounded Theory. Thousand Oaks, CA: Sage Publications; 2014.
BaldacchinoA, GilchristG, FlemingR, BannisterJ. Guilty until proven innocent: a qualitative study of the management of chronic non-cancer pain among patients with a history of substance abuse. Addict Behav.2010;35:270–272.
57.
CiceroTJ, KurtzSP, SurrattHL, . Multiple determinants of specific modes of prescription opioid diversion. J Drug Issues.2011;41:283–304.
58.
BelcherJ, NielsenS, CampbellG, . Diversion of prescribed opioids by people living with chronic pain: results from an Australian community sample. Drug Alcohol Rev.2014;33:27–32.
59.
Physician liability: when an overdose brings a lawsuit. American Medical News web site. amednews.com. Published 2013. Accessed October 24, 2016
60.
MarieBSt. Primary care experiences of people who live with chronic pain and receive opioids to manage pain: a qualitative methodology. J Am Assoc Nurse Pract.2016;28:429–435.
61.
CoganJ, OuimetteMF, Vargas-SchafferG, YeginZ, DeschampsA, DenaultA. Patient attitudes and beliefs regarding pain medication after cardiac surgery: barriers to adequate pain management. Pain Manag Nurs.2014;15:574–579.
62.
ConrardyM, LankP, CameronKA, McConnellR, ChevrierA, SearsJ, AhlstromE, WolfMS, CourtneyDM, McCarthyDM. Emergency department patient perspectives on the risk of addiction to prescription opioids. Pain Med.2015;17:114–121.
63.
BlakeS, RuelB, SeamarkC, SeamarkD. Experiences of patients requiring strong opioid drugs for chronic non-cancer pain: a patient-initiated study. Br J Gen Pract.2007;57:101–108.
64.
KellyJF, WakemanSE, SaitzR. Stop talking ‘dirty’: clinicians, language, and quality of care for the leading cause of preventable death in the United States. Am J Med.2015;128:8–9.
65.
KeaneH. Categorising methadone: addiction and analgesia. Int J Drug Policy.2013;24:e18–e24.
66.
BarclayJS, OwensJE, BlackhallLJ. Screening for substance abuse risk in cancer patients using the Opioid Risk Tool and urine drug screen. Support Care Cancer.2014;22:1883–1888.
67.
MooreTM, JonesT, BrowderJH, DaffronS, PassikSD. A comparison of common screening methods for predicting aberrant drug-related behavior among patients receiving opioids for chronic pain management. Pain Med.2009;10:1426–1433.
68.
DaniulaityteR, FalckR, CarlsonRG. “I'm not afraid of those ones just ‘cause they've been prescribed”: perceptions of risk among illicit users of pharmaceutical opioids. Int J Drug Policy.2012;23:374–384.
69.
LordS, BrevardJ, BudmanS. Connecting to young adults: an online social network survey of beliefs and attitudes associated with prescription opioid misuse among college students. Subst Use Misuse.2011;46:66–76.
70.
FrankD, Mateu-GelabertP, GuarinoH, BennettA, WendelT, JessellL, TeperA. High risk and little knowledge: overdose experiences and knowledge among young adult nonmedical prescription opioid users. Int J Drug Policy.2014;26:84–91.
71.
WilderCM, MillerSC, TiffanyE, WinhusenT, WinstanleyEL, SteinMD. Risk factors for opioid overdose and awareness of overdose risk among veterans prescribed chronic opioids for addiction or pain. J Addict Dis.2016;35:42–51.
72.
Banta-GreenCJ, Von KorffM, SullivanMD, MerrillJO, DoyleSR, SaundersK. The prescribed opioids difficulties scale: a patient-centered assessment of problems and concerns. Clin J Pain.2010;26:489–497.
73.
BrownVJ. Risk perception: it's personal. Environ Health Perspect.2014;122:A276–A279.
74.
MatthiasMS, KrebsEE, BergmanAA, CoffingJM, BairMJ. Communicating about opioids for chronic pain: a qualitative study of patient attributions and the influence of the patient-physician relationship. Eur J Pain.2014;18:835–843.
75.
BeckerWC, SullivanLE, TetraultJM, DesaiRA, FiellinDA. Non-medical use, abuse and dependence on prescription opioids among U.S. adults: psychiatric, medical and substance use correlates. Drug Alcohol Depend.2008;94:38–47.
76.
Office of the National Drug Control Policy 2014. The National Drug Control Strategy. Washington, DC: Executive Office of the President; 2014.
77.
World Health Organization. Community Management of Opioid Overdose. Geneva, Switzerland: World Health Organization; 2014.
78.
BazaziAR, ZallerND, FuJJ, RichJD. Preventing opiate overdose deaths: examining objections to take-home naloxone. J Health Care Poor Underserved.2010;21:1108–1113.
79.
BinswangerIA, KoesterS, MuellerSR, GardnerEM, GoddardK, GlanzJM. Overdose education and naloxone for patients prescribed opioids in primary care: a qualitative study of primary care staff. J Gen Intern Med.2015;30:1837–1844.
80.
BeletskyL, RuthazerR, MacalinoGE, RichJD, TanL, BurrisS. Physicians’ knowledge of and willingness to prescribe naloxone to reverse accidental opiate overdose: challenges and opportunities. J Urban Health.2007;84:126–136.
81.
BeharE, SantosGM, WheelerE, RoweC, CoffinPO. Brief overdose education is sufficient for naloxone distribution to opioid users. Drug Alcohol Depend.2015;148:209–212.
82.
BeletskyL, RichJD, WalleyAY. Prevention of fatal opioid overdose. JAMA.2012;308:1863–1864.
